<DOC>
	<DOC>NCT01843855</DOC>
	<brief_summary>The study is being undertaken to understand how a gastric bypass can affect a subject's diabetes even prior to their losing significant amounts of weight. The hypothesis of this study is that increased glucagon-like peptide-1 (GLP-1) secretion explains the amelioration in insulin secretion after Roux-en-Y Gastric Bypass (RYGB) surgery.</brief_summary>
	<brief_title>The Contribution of Incretin Hormones to the Amelioration of Glucose Metabolism After Roux-en-Y Gastric Bypass</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Gastric Inhibitory Polypeptide</mesh_term>
	<mesh_term>Incretins</mesh_term>
	<criteria>Subjects with type 2 diabetes mellitus or impaired fasting glucose concentration of &gt; 110 mg/dL Subjects registered to receive a RouxenY Gastric Bypass (RYGB). Subjects taking thiazolidinediones Subjects with active systemic illness Subjects with active microvascular or macrovascular complications of their diabetes For female subject: positive pregnancy test at the time of enrollment in study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Gastric Bypass</keyword>
	<keyword>bariatric surgery</keyword>
	<keyword>glucose metabolism</keyword>
</DOC>